Self-aggregated nanoparticles of cholesterol-modified chitosan conjugate as a novel carrier of epirubicin

Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis

“…The high drug capacity of the drug-conjugated (27.6 wt%) system was greater than that of the drug-encapsulated system by approximately two-to fourfold. 10,39,40 In addition, the binding capacity was also much higher than that of a previous system in which PAA-MNPs were used as the nanocarrier for rtPA via covalent binding (276 µg rtPA/mg MNCs versus 67 µg rtPA/mg PAA-MNPs), 9 allowing for the reduction of MNCs required to deliver the same dosage of rtPA to achieve similar target thrombolysis. The polymer coating of the MNCs in the current study likely possessed a long side chain with four carbons that provided greater freedom of motion with less steric hindrance, whereas PAA chains tend to swell, extend, and dissolve in aqueous solution due to exhibition of pH-dependent swelling behavior in the aqueous solution.…”

Nanoparticles Based on Modified Polysaccharides

“…Conjugating hydrophobic cholesterol to hydrophilic polysaccharides may form amphiphilic copolymer which may further form self-assembly nanoparticles in aqueous solution. cholesterol-modified chitosan conjugate with succinyl linkages was synthesized (Wang et al, 2007c). The conjugates formed monodisperse self-aggregated www.intechopen.com nanoparticles with a roughly spherical shape and a mean diameter of 417.2 nm by probe sonication in aqueous media.…”

Polysaccharide-Based Nanoparticles for Controlled Release Formulations

“…Cholesterol attached to pullulans of different molecular weights, or to chitosan, allow to obtain nanoparticles of very small sizes: 20-30 nm in case of cholesterolpullulans based nanoparticles (Akiyoshi et al, 1998) and 417 nm in case of cholesterolchitosan systems (Wang et al, 2007). Apart from cholesterol, 5 -Cholanic acid is a non-toxic bile acid present in humans that can be chosen as the hydrophobic moiety to be attached to hyaluronic acid in order to form amphiphilic conjugates.…”

“…Therefore, nanoparticles being used as a carrier of epirubicin are hoped to sustain its release, prolong its circulation time, enhance its therapeutic index and decrease its toxic effects. Cholesterolmodified nanoparticles have been prepared by self-assembling method by Wang and coworkers (Wang et al, 2007). They synthesized cholesterol-modified chitosan conjugate with succinyl linkages, investigated its self-aggregation behaviour, and prepared self-aggregated nanoparticles by sonication in aqueous media.…”